A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting ...
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results